Abstract
Ischemic stroke is responsible for about one third of all deaths in industrialized countries and is the major cause of serious, long-term disability in adults over the age of 45. It stands to reason that there is a need for pharmacotherapy to treat acute ischemic stroke. In over two decades of research, the hope of developing a neuroprotective drug that effectively reduces the severity of damage after stroke has not been realized. However, considerable insights have been gained into the mechanisms and cascade of events that occurs following stroke as well as an improved understanding of neuronal injury and cell death. Recent studies in humans indicate many parallels with animal studies not only in the nature of events following ischemia, but also in their time course. Multiple pathways are known to be involved and yet the majority of treatments are still being designed to target a single effector in these pathways. Combinations of drugs, or drugs, which have multiple actions, targeting several pathways may prove to be a more successful strategy.
Keywords: stroke, neuroprotection, combination therapy, hybrid drugs, antioxidants, pharmacotherapy
Current Neuropharmacology
Title: Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Volume: 2 Issue: 3
Author(s): Jennifer K. Callaway
Affiliation:
Keywords: stroke, neuroprotection, combination therapy, hybrid drugs, antioxidants, pharmacotherapy
Abstract: Ischemic stroke is responsible for about one third of all deaths in industrialized countries and is the major cause of serious, long-term disability in adults over the age of 45. It stands to reason that there is a need for pharmacotherapy to treat acute ischemic stroke. In over two decades of research, the hope of developing a neuroprotective drug that effectively reduces the severity of damage after stroke has not been realized. However, considerable insights have been gained into the mechanisms and cascade of events that occurs following stroke as well as an improved understanding of neuronal injury and cell death. Recent studies in humans indicate many parallels with animal studies not only in the nature of events following ischemia, but also in their time course. Multiple pathways are known to be involved and yet the majority of treatments are still being designed to target a single effector in these pathways. Combinations of drugs, or drugs, which have multiple actions, targeting several pathways may prove to be a more successful strategy.
Export Options
About this article
Cite this article as:
Callaway K. Jennifer, Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359602
DOI https://dx.doi.org/10.2174/1570159043359602 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Niacin: From Mechanisms of Action to Therapeutic Uses
Mini-Reviews in Medicinal Chemistry Prostacyclin Synthase Gene: Implication and Prevention of Cardiovascular Disease
Vascular Disease Prevention (Discontinued) The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Editorial [Hot Topic Cells, Micro- and Nanosystems in Reconstructive Medicine: Past, Present, and Future Guest Editors: Christian Andressen & Andreas Wree]
Current Pharmaceutical Biotechnology Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Opportunities and Challenges for Niosomes as Drug Delivery Systems
Current Drug Delivery Editorial [Hot Topic: The Medicinal Chemistry of Agents Targeting the Nuclear Hormone Receptor Guest Editor: John Regan ]
Current Topics in Medicinal Chemistry Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery Mechanisms of Thrombosis, Available Treatments and Management Challenges Presented by Thromboangiitis Obliterans
Current Medicinal Chemistry Influence of a High-Fat Diet on Cardiac iNOS in Female Rats
Current Vascular Pharmacology Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials
Current Medicinal Chemistry PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Dexmedetomidine: A Review of its Use for the Management of Pain, Agitation, and Delirium in the Intensive Care Unit
Current Pharmaceutical Design Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Clinical Impacts in Cardiovascular Molecular Imaging: the Example of Cardiac Sympathetic Imaging in Heart Failure
Current Medical Imaging The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Management of the Metabolic Syndrome as a Strategy for Preventing the Macrovascular Complications of Type 2 Diabetes: Controversial Issues
Current Diabetes Reviews Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry